Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Operating Leases (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Operating Leases data on record, last reported at $7.5 million in Q4 2025.

  • For Q4 2025, Operating Leases changed 0.17% year-over-year to $7.5 million; the TTM value through Dec 2025 reached $7.5 million, changed 0.17%, while the annual FY2025 figure was $7.5 million, 0.17% changed from the prior year.
  • Operating Leases reached $7.5 million in Q4 2025 per PLSE's latest filing, up from $7.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $10.2 million in Q3 2021 and bottomed at $7.2 million in Q1 2025.
  • Average Operating Leases over 5 years is $8.6 million, with a median of $8.6 million recorded in 2023.
  • Peak YoY movement for Operating Leases: decreased 25.23% in 2021, then grew 13.08% in 2022.
  • A 5-year view of Operating Leases shows it stood at $8.1 million in 2021, then increased by 13.08% to $9.1 million in 2022, then changed by 0.0% to $9.1 million in 2023, then dropped by 17.51% to $7.5 million in 2024, then fell by 0.17% to $7.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $7.5 million in Q4 2025, $7.2 million in Q1 2025, and $7.5 million in Q4 2024.